In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria.
Martinez-Turrillas R, Martin-Mallo A, Rodriguez-Diaz S, Zapata-Linares N, Rodriguez-Marquez P, San Martin-Uriz P, Vilas-Zornoza A, Calleja-Cervantes ME, Salido E, Prosper F, Rodriguez-Madoz JR
Mol Ther Methods Clin Dev. 2022 Mar 16;25:137-146. doi: 10.1016/j.omtm.2022.03.006. eCollection 2022 Jun 9.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
No plasmids are currently publicly available from Addgene for this article.